• Issue

    Hepatology: Volume 54, Issue 1

    1-379
    July 2011
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Comments from the Editors

Free Access

Liver cancer: Still a long way to go†

Jordi Bruix MD, 
  • Pages: 1-2
  • First Published: 26 June 2011

Editorials

Free Access

Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail†‡

Michael Charlton MD, FRCP, 
  • Pages: 3-5
  • First Published: 26 June 2011
Free Access

Mortality in nonalcoholic fatty liver disease: Clues from the cremona study†‡

Leon A. Adams MBBS, Ph.D., 
  • Pages: 6-8
  • First Published: 26 May 2011
Free Access

Dr. Jekyll and Mr. Hyde: A paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer†‡

Diego F. Calvisi M.D., 
  • Pages: 9-12
  • First Published: 23 May 2011
Free Access

Death receptors and mitochondria: Life depends on the liver†‡

Melissa J. Parsons Ph.D.,  Douglas R. Green Ph.D., 
  • Pages: 13-15
  • First Published: 11 May 2011
Free Access

Liver and serum iron: Discrete regulators of hepatic hepcidin expression†‡

Anita C. G. Chua PhD,  Debbie Trinder PhD,  John K. Olynyk BMedSc, MBBS, FRACP, MD, 
  • Pages: 16-19
  • First Published: 26 May 2011

Viral Hepatitis

Free Access

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus†‡

Varun Garg,  Rolf van Heeswijk,  Jee Eun Lee,  Katia Alves,  Priya Nadkarni,  Xia Luo, 
  • Pages: 20-27
  • First Published: 26 May 2011
Free Access

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells†

Itziar Echeverria,  Alexander Pereboev,  Leyre Silva,  Aintzane Zabaleta,  José Ignacio Riezu-Boj,  Marta Bes,  María Cubero,  Francisco Borras-Cuesta,  Juan José Lasarte,  Juan Ignacio Esteban,  Jesús Prieto,  Pablo Sarobe, 
  • Pages: 28-37
  • First Published: 30 March 2011
Free Access

Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets†

Sophie Clément,  Marion Peyrou,  Andrea Sanchez-Pareja,  Lucie Bourgoin,  Pierluigi Ramadori,  David Suter,  Manlio Vinciguerra,  Kevin Guilloux,  Stephanie Pascarella,  Laura Rubbia-Brandt,  Francesco Negro,  Michelangelo Foti, 
  • Pages: 38-49
  • First Published: 04 April 2011
Free Access

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients†

Frank Wagner,  Robert Thompson,  Constantino Kantaridis,  Paul Simpson,  Philip J. F. Troke,  Shyla Jagannatha,  Srividya Neelakantan,  Vivek S. Purohit,  Jennifer L. Hammond, 
  • Pages: 50-59
  • First Published: 12 April 2011
Free Access

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C†‡

Eric Trépo,  Pierre Pradat,  Andrej Potthoff,  Yukihide Momozawa,  Eric Quertinmont,  Thierry Gustot,  Arnaud Lemmers,  Pascale Berthillon,  Leila Amininejad,  Michéle Chevallier,  Jerome Schlué,  Hans Kreipe,  Jacques Devière,  Michael Manns,  Christian Trépo,  John Sninsky,  Heiner Wedemeyer,  Denis Franchimont,  Christophe Moreno, 
  • Pages: 60-69
  • First Published: 12 April 2011
Free Access

Racial differences in hepatitis C treatment eligibility†‡

Michael T. Melia,  Andrew J. Muir,  Jonathan McCone,  Mitchell L. Shiffman,  John W. King,  Steven K. Herrine,  Greg W. Galler,  Joseph R. Bloomer,  Frederick A. Nunes,  Kimberly A. Brown,  Kevin D. Mullen,  Natarajan Ravendhran,  Reem H. Ghalib,  Navdeep Boparai,  Ruiyun Jiang,  Stephanie Noviello,  Clifford A. Brass,  Janice K. Albrecht,  John G. McHutchison,  Mark S. Sulkowski,  on behalf of the IDEAL Study Team , 
  • Pages: 70-78
  • First Published: 12 April 2011
Free Access

Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel†‡

Toshana L. Foster,  Mark Verow,  Ann L. Wozniak,  Matthew J. Bentham,  Joseph Thompson,  Elizabeth Atkins,  Steven A. Weinman,  Colin Fishwick,  Richard Foster,  Mark Harris,  Stephen Griffin, 
  • Pages: 79-90
  • First Published: 21 April 2011
Free Access

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study†

Yun-Fan Liaw,  Maria Raptopoulou-Gigi,  Hugo Cheinquer,  Shiv Kumar Sarin,  Tawesak Tanwandee,  Nancy Leung,  Cheng-Yuan Peng,  Robert P. Myers,  Robert S. Brown Jr,  Lennox Jeffers,  Naoky Tsai,  Jolanta Bialkowska,  Shijie Tang,  Suzanne Beebe,  Elizabeth Cooney, 
  • Pages: 91-100
  • First Published: 18 April 2011
Free Access

Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy†‡§

Chao-Wei Hsu,  Chau-Ting Yeh, 
  • Pages: 101-108
  • First Published: 18 April 2011
Free Access

Krüppel-like factor 15 activates hepatitis B virus gene expression and replication†‡

Jie Zhou,  Thomas Tan,  Yongjun Tian,  Bojian Zheng,  J.-H. James Ou,  Eric J. Huang,  T.S. Benedict Yen, 
  • Pages: 109-121
  • First Published: 18 April 2011

Steatohepatitis/Metabolic Liver Disease

Free Access

Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis†‡

Jiang Wei Wu,  Shu Pei Wang,  Fernando Alvarez,  Stéphanie Casavant,  Nicolas Gauthier,  Lynda Abed,  Krishnakant G. Soni,  Gongshe Yang,  Grant A. Mitchell, 
  • Pages: 122-132
  • First Published: 04 April 2011
Free Access

Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells†‡

Timea Csak,  Michal Ganz,  Justin Pespisa,  Karen Kodys,  Angela Dolganiuc,  Gyongyi Szabo, 
  • Pages: 133-144
  • First Published: 12 April 2011
Free Access

Fatty liver index and mortality: The cremona study in the 15th year of follow-up†‡§

Giliola Calori,  Guido Lattuada,  Francesca Ragogna,  Maria Paola Garancini,  Paolo Crosignani,  Marco Villa,  Emanuele Bosi,  Giacomo Ruotolo,  Lorenzo Piemonti,  Gianluca Perseghin, 
  • Pages: 145-152
  • First Published: 12 April 2011
Free Access

Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis†

Balu K. Chacko,  Anup Srivastava,  Michelle S. Johnson,  Gloria A. Benavides,  Mi Jung Chang,  Yaozu Ye,  Nirag Jhala,  Michael P. Murphy,  Balaraman Kalyanaraman,  Victor M. Darley-Usmar, 
  • Pages: 153-163
  • First Published: 21 April 2011

Hepatobiliary Malignancies

Free Access

p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma†‡§

Doris Schneller,  Georg Machat,  Alexandra Sousek,  Verena Proell,  Franziska van Zijl,  Gudrun Zulehner,  Heidemarie Huber,  Markus Mair,  Markus K. Muellner,  Sebastian M.B. Nijman,  Robert Eferl,  Richard Moriggl,  Wolfgang Mikulits, 
  • Pages: 164-172
  • First Published: 30 March 2011
Free Access

Risk factors for cholangiocarcinoma†‡§

Gia L. Tyson,  Hashem B. El-Serag, 
  • Pages: 173-184
  • First Published: 12 April 2011
Free Access

Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein kinase†‡§

Hayato Nakagawa,  Yoshihiro Hirata,  Kohsuke Takeda,  Yoku Hayakawa,  Takehiro Sato,  Hiroto Kinoshita,  Kei Sakamoto,  Wachiko Nakata,  Yohko Hikiba,  Masao Omata,  Haruhiko Yoshida,  Kazuhiko Koike,  Hidenori Ichijo,  Shin Maeda, 
  • Pages: 185-195
  • First Published: 12 April 2011

Autoimmune, Cholestatic and Biliary Disease

Free Access

Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis†‡

Guanghua Rong,  Renqian Zhong,  Ana Lleo,  Patrick S.C. Leung,  Christopher L. Bowlus,  Guo-Xiang Yang,  Chen-Yen Yang,  Ross L. Coppel,  Aftab A. Ansari,  Dean A. Cuebas,  Howard J. Worman,  Pietro Invernizzi,  Gregory J. Gores,  Gary Norman,  Xiao-Song He,  M. Eric Gershwin, 
  • Pages: 196-203
  • First Published: 12 April 2011

Liver Failure/Cirrhosis/Portal Hypertension

Free Access

Microglia activation in hepatic encephalopathy in rats and humans†‡

Irina Zemtsova,  Boris Görg,  Verena Keitel,  Hans-Jürgen Bidmon,  Karsten Schrör,  Dieter Häussinger, 
  • Pages: 204-215
  • First Published: 30 March 2011

Liver Injury/Regeneration

Free Access

Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation†‡

Shinya Ueki,  Antonino Castellaneta,  Osamu Yoshida,  Kikumi Ozaki,  Matthew Zhang,  Shoko Kimura,  Kumiko Isse,  Mark Ross,  Lifang Shao,  Donna B. Stolz,  Angus W. Thomson,  Anthony J. Demetris,  David A. Geller,  Noriko Murase, 
  • Pages: 216-228
  • First Published: 18 April 2011
Free Access

Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice†‡§

Cheng Ji,  Neil Kaplowitz,  Mo Yin Lau,  Eddy Kao,  Lydia M. Petrovic,  Amy S. Lee, 
  • Pages: 229-239
  • First Published: 18 April 2011

Liver Biology/Pathobiology

Free Access

Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice†‡

Hayato Hikita,  Tetsuo Takehara,  Takahiro Kodama,  Satoshi Shimizu,  Minoru Shigekawa,  Atsushi Hosui,  Takuya Miyagi,  Tomohide Tatsumi,  Hisashi Ishida,  Wei Li,  Tatsuya Kanto,  Naoki Hiramatsu,  Shigeomi Shimizu,  Yoshihide Tsujimoto,  Norio Hayashi, 
  • Pages: 240-251
  • First Published: 21 March 2011
Free Access

In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression†

Ogyi Park,  Hua Wang,  Honglei Weng,  Lionel Feigenbaum,  Hai Li,  Shi Yin,  Sung Hwan Ki,  Seong Ho Yoo,  Steven Dooley,  Fu-Sheng Wang,  Howard A. Young,  Bin Gao, 
  • Pages: 252-261
  • First Published: 04 April 2011
Free Access

Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism†‡

Frank A. Schildberg,  Alexandra Wojtalla,  Sören V. Siegmund,  Elmar Endl,  Linda Diehl,  Zeinab Abdullah,  Christian Kurts,  Percy A. Knolle, 
  • Pages: 262-272
  • First Published: 12 April 2011
Free Access

Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice†‡

Elena Corradini,  Delphine Meynard,  Qifang Wu,  Shan Chen,  Paolo Ventura,  Antonello Pietrangelo,  Jodie L. Babitt, 
  • Pages: 273-284
  • First Published: 12 April 2011
Free Access

The metastasis-associated protein-1 gene encodes a host permissive factor for schistosomiasis, a leading global cause of inflammation and cancer†‡

Sujit S. Nair,  Anitha Bommana,  Jeffrey M. Bethony,  Amanda J. Lyon,  Kazufumi Ohshiro,  Suresh B. Pakala,  Gabriel Rinaldi,  Brian Keegan,  Sutas Suttiprapa,  Maria V. Periago,  Peter J. Hotez,  Paul J. Brindley,  Rakesh Kumar, 
  • Pages: 285-295
  • First Published: 12 April 2011
Free Access

Mitochondrial calcium regulates rat liver regeneration through the modulation of apoptosis†‡

Mateus T. Guerra,  Emerson A. Fonseca,  Flavia M. Melo,  Viviane A. Andrade,  Carla J. Aguiar,  Lídia M. Andrade,  Ana Cristina N. Pinheiro,  Marisa C. F. Casteluber,  Rodrigo R. Resende,  Mauro C. X. Pinto,  Simone O. A. Fernandes,  Valbert N. Cardoso,  Elaine M. Souza-Fagundes,  Gustavo B. Menezes,  Ana M. de Paula,  Michael H. Nathanson,  Maria de Fátima Leite, 
  • Pages: 296-306
  • First Published: 18 April 2011
Free Access

Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition†‡

Kit-Ying Chung,  Ibis K.-C. Cheng,  Arthur K.-K. Ching,  Jian-Hong Chu,  Paul B.-S. Lai,  Nathalie Wong, 
  • Pages: 307-318
  • First Published: 21 April 2011
Free Access

Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis†‡§

Núria Tarrats,  Anna Moles,  Albert Morales,  Carmen García-Ruiz,  José C. Fernández-Checa,  Montserrat Marí, 
  • Pages: 319-327
  • First Published: 26 April 2011

AASLD Practice Guidelines

Open Access

Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases†‡

Bruce R. Bacon,  Paul C. Adams,  Kris V. Kowdley,  Lawrie W. Powell,  Anthony S. Tavill, 
  • Pages: 328-343
  • First Published: 30 March 2011

Meeting Reports

Free Access

Endpoints and clinical trial design for nonalcoholic steatohepatitis†‡

Arun J. Sanyal,  Elizabeth M. Brunt,  David E. Kleiner,  Kris V. Kowdley,  Naga Chalasani,  Joel E. Lavine,  Vlad Ratziu,  Arthur McCullough, 
  • Pages: 344-353
  • First Published: 21 April 2011

Hepatology Elsewhere

Free Access

Anti-chemokine therapy for the treatment of hepatic fibrosis: An attractive approach†

Grant A. Ramm Ph.D., 
  • Pages: 354-358
  • First Published: 26 June 2011
Free Access

Copper toxicity in Wilson disease explained in a new way†

Uta Merle M.D.,  Wolfgang Stremmel M.D., 
  • Pages: 358-360
  • First Published: 26 June 2011
Free Access

A glimpse at the future of hepatitis C therapy: The INFORM trial†

Lei Y. Lim M.D.,  Paul Y. Kwo M.D., 
  • Pages: 360-363
  • First Published: 26 June 2011

Image of the Month

Free Access

The wet-ascitic form of tuberculous peritonitis†

Sandeep M. Patel M.D.,  Seth Sweetser M.D., 
  • Pages: 364-365
  • First Published: 10 February 2011

Correspondence

Free Access

Inflammation does not always kill hepatocytes during liver damage†

Honglei Weng Ph.D.,  Hai Li M.D.,  Steven Dooley Ph.D., 
  • Page: 366
  • First Published: 10 January 2011
Free Access

Reply:†

Norio Horiguchi M.D., Ph.D.,  Bin Gao M.D., Ph.D., 
  • Pages: 367-368
  • First Published: 21 April 2011
Free Access

Screening for biliary atresia: Swiss stool color card†‡

Barbara E. Wildhaber M.D., 
  • Page: 368
  • First Published: 12 April 2011
Free Access

Reply:†

Tien-Hau Lien M.D.,  Mei-Hwei Chang M.D., 
  • Page: 369
  • First Published: 21 April 2011
Free Access

Misuse of scoring systems†

Elizabeth M. Brunt M.D.,  David E. Kleiner M.D., Ph.D.,  Cynthia Behling M.D., Ph.D.,  Melissa J. Contos M.D.,  Oscar W. Cummings M.D.,  Linda D. Ferrell M.D.,  Michael S. Torbenson M.D.,  Matthew Yeh M.D., Ph.D., 
  • Pages: 369-370
  • First Published: 12 April 2011
Free Access

Reply:†

Zachary Goodman M.D., Ph.D.,  Hala Makhlouf M.D., Ph.D.,  Zobair Younossi M.D., M.P.H., 
  • Pages: 370-371
  • First Published: 26 April 2011
Free Access

Efforts at making the diagnosis of acute-onset autoimmune hepatitis†

Keiichi Fujiwara M.D.,  Shin Yasui M.D.,  Osamu Yokosuka M.D., 
  • Pages: 371-372
  • First Published: 30 March 2011
Free Access

Autoimmune acute liver failure†

Jean-Charles Duclos-Vallée M.D., Ph.D.,  Philippe Ichai M.D.,  Didier Samuel M.D., Ph.D., 
  • Page: 372
  • First Published: 04 April 2011
Free Access

Reply:†

R. Todd Stravitz M.D.,  Jay H. Lefkowitch M.D., 
  • Pages: 372-373
  • First Published: 21 April 2011
Free Access

Occult hepatitis b virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C†

Giovanni Raimondo M.D.,  Teresa Pollicino M.D.,  Massimo Levrero M.D.,  Antonio Craxì M.D., 
  • Page: 373
  • First Published: 21 April 2011
Free Access

Reply:†‡§

Anna S. Lok M.D.,  James E. Everhart M.D., 
  • Pages: 373-374
  • First Published: 11 May 2011
Free Access

Association between human leukocyte antigen DP gene polymorphisms and chronic hepatitis B in a Chinese population†‡§

Chibo Liu M.B., 
  • Page: 375
  • First Published: 11 May 2011
Free Access

Reply:†

Xiuchan Guo M.D.,  Randy Johnson Ph.D.,  Stephen J. O'Brien Ph.D., 
  • Pages: 375-376
  • First Published: 26 May 2011
Free Access

Neutralization of lipopolysaccharide effects in liver diseases, the quest for the holy grail†

Arnaud Galbois M.D.,  Dominique Thabut M.D., Ph.D.,  Richard Moreau M.D., Ph.D.,  Didier Lebrec M.D., Ph.D., 
  • Page: 376
  • First Published: 12 January 2011
Free Access

Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead†

Edoardo G. Giannini M.D., Ph.D.,  Fabio Farinati M.D.,  Franco Trevisani M.D., 
  • Pages: 376-377
  • First Published: 19 January 2011
Free Access

Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease†

Liang Shen Ph.D., 
  • Pages: 377-378
  • First Published: 31 January 2011
Free Access

Are there more factors other than hepatitis B virus DNA level and A1762T/G1764A mutation in liver tissue that also independently predict postoperative survival in hepatocellular carcinoma?†

Yong-Ning Xin,  Zhong-Hua Lin,  Shi-Ying Xuan, 
  • Page: 378
  • First Published: 05 April 2011
Free Access

Risk factors for infection in chronic hepatitis C: A high prevalence of sexual exposure among human immunodeficiency virus–coinfected women†

Eduardo Fassio M.D.,  Graciela Landeira M.D.,  Cristina Longo M.D.,  Nora Domínguez M.D.,  Estela Alvarez M.D.,  Gisela Gualano M.D., 
  • Page: 379
  • First Published: 11 February 2011